Phase II Study to Investigate the Safety and Efficacy of 2 Dose Levels of a Novel Glucagon Formulation Compared to Commercially Available Glucagon in Type 1 Diabetic Patients Following Insulin-induced Hypoglycemia
Latest Information Update: 07 Nov 2021
Price :
$35 *
At a glance
- Drugs Glucagon (Primary) ; Glucagon (Primary)
- Indications Type 1 diabetes mellitus
- Focus Adverse reactions; Therapeutic Use
- Sponsors AMG Medical; Eli Lilly and Company (India) Pvt. Ltd
- 09 Aug 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 27 Jan 2014 New trial record